Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161)

ABSTRACT: Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161)

PROVIDER: PRJNA507104 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [array]

Project description:Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [array]

| PRJNA504559 | ENA

Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [seq]

Project description:Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [seq]

| PRJNA507110 | ENA

Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [seq]

Project description:The aim was to identify the effect of caspase inhibition on changes in gene expression in MCF-7 cells induced by a combination of TRAIL and LCL-161. Treated samples and control samples were collected after 24 h of treatment.

2021-02-24 | GSE122979 | GEO

Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161) [array]

Project description:The aim was to identify changes in gene expression in MCF-7 cells induced by a combination of TRAIL and LCL-161. Treated samples and control samples were collected after 24 h of treatment and after 96 h of treatment followed by a three-day period in normal medium.

2022-06-30 | GSE122307 | GEO

Treatment of MCF-7 cells with TRAIL and Smac mimetic (LCL-161)

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-02-24 | GSE122980 | GEO

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells.

Project description: Not available

| S-EPMC6941266 | biostudies-literature

Expression data from MDA-MB-231 parental and xenograft tumor cells treated with Smac mimetic SM-164.

Project description:Small-molecule Smac mimetics target inhibitor of apoptosis (IAP) proteins to induce TNFÎ±-dependent apoptosis in cancer cells and several Smac mimetics have been advanced into clinical development as a new class of anticancer drugs. However, preclinical studies have shown that only a small subset of cancer cell lines are sensitive to Smac mimetics used as single agents and these cell lines are at risk of developing drug resistance to Smac mimetics. Thus, it is important to understand the molecular mechanisms underlying intrinsic and acquired resistance of cancer cells to Smac mimetics in order to develop effective therapeutic strategies to overcome or prevent Smac mimetic resistance. We established Smac mimetic resistant sublines derived from MDA-MB-231 breast cancer cells, which exhibit exquisite sensitivity to the Smac mimetic SM-164, and used microarrays to detail the global programme of gene expression underlying SM-164 resistance in MDA-MB-231 cells and identified differentially expressed genes in SM-164-resistant and -sensitive MDA-MB-231 cells. SCID mice with MDA-MB-231 xenograft tumors were treated with 5 mg/kg of SM-164 intravenously for 5 days/week for 2 weeks. SM-164-regressed MDA-MB-231 tumors regrew after treatment ended. Tumor cells from these regrown MDA-MB-231 tumors were isolated and total RNAs were prepared for microarray analysis.

2012-03-01 | E-GEOD-33827 | biostudies-arrayexpress

Expression data from MDA-MB-231 parental and xenograft tumor cells treated with Smac mimetic SM-164.

Project description:Small-molecule Smac mimetics target inhibitor of apoptosis (IAP) proteins to induce TNFα-dependent apoptosis in cancer cells and several Smac mimetics have been advanced into clinical development as a new class of anticancer drugs. However, preclinical studies have shown that only a small subset of cancer cell lines are sensitive to Smac mimetics used as single agents and these cell lines are at risk of developing drug resistance to Smac mimetics. Thus, it is important to understand the molecular mechanisms underlying intrinsic and acquired resistance of cancer cells to Smac mimetics in order to develop effective therapeutic strategies to overcome or prevent Smac mimetic resistance. We established Smac mimetic resistant sublines derived from MDA-MB-231 breast cancer cells, which exhibit exquisite sensitivity to the Smac mimetic SM-164, and used microarrays to detail the global programme of gene expression underlying SM-164 resistance in MDA-MB-231 cells and identified differentially expressed genes in SM-164-resistant and -sensitive MDA-MB-231 cells.

2012-03-01 | GSE33827 | GEO

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.

Project description: Not available

| S-EPMC6290104 | biostudies-literature

Microarray analysis of in-vitro differentiated murine Th17 cells in the presence of the smac mimetic AT406, or DMSO as control, and undifferentiated naive CD4 T cells.

Project description:Transcriptome analysis to investigate the effects of the smac mimetic AT406 on the differentiation of murine Th17 cells compared to DMSO controls, and to investigate the transriptome of murine Th17 cells compared to control undifferentiated naive CD4 T cells.

2019-08-15 | E-MTAB-7894 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data